z-logo
open-access-imgOpen Access
Effect of nasal irrigation on allergic rhinitis control in children; complementarity between CARAT and MASK outcomes
Author(s) -
Mitsias Dimitrios I.,
Dimou Maria V.,
Lakoumentas John,
Alevizopoulos Konstantinos,
SousaPinto Bernardo,
Fonseca Joao A.,
Bousquet Jean,
Papadopoulos Nikolaos G.
Publication year - 2020
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/s13601-020-00313-2
Subject(s) - medicine , allergy , clinical endpoint , randomized controlled trial , adjunctive treatment , physical therapy , asthma , pediatrics , immunology
Background Nasal irrigations (NI) are increasingly used as an over‐the‐counter adjunctive treatment for allergic rhinitis (AR), but clinical studies on their effectiveness are limited. Methods An open‐label, controlled, non‐randomized, real‐life study was conducted to evaluate the effectiveness of NI with a new hypertonic solution as add‐on treatment for AR. Children and adolescents with AR were prescribed symptomatic treatment. The active group also received an additional sea‐water NI solution supplemented with algae extracts. The primary endpoint was symptom control, assessed by the control of allergic rhinitis and asthma test (CARAT) questionnaires. Moreover, the MASK/Allergy Diary was used to track symptoms and daily medication use that were combined in a novel total symptom/medication score (TSMS). Results We assessed 76 patients. Overall, there was a significant improvement of CARAT results (median Z‐score change of 1.1 in the active/NI group vs. 0.4 in the control group; p  = 0.035). Among patients > 12 years old (n = 51), there was a significant improvement in CARAT10 results among participants receiving NI (21.0 to 25.5; p  < 0.001), but not in the regular treatment group (21.5 to 24.0; p  = 0.100). For children < 12 years old (n = 25), the ΝΙ group had significantly improved symptom control (CARATKids results: 5.0 to 2.0; p  = 0.002), in contrast to the control group (4.0 to 2.5; p  = 0.057). MASK data on allergic symptoms were comparable between groups. However, the NI group had lower TSMS, more days with < 20% symptoms and fewer days using symptomatic treatment (26.9% vs. 43.5%; p  = 0.005). Conclusion Addition of NI with a sea‐water solution to regular treatment improved AR symptom control. CARAT questionnaires and MASK application can be useful outcome tools in real‐life studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here